|
Sep 26
|
Fortress Biotech to Participate in October 2024 Investor Conferences
|
|
Sep 20
|
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
|
|
Jul 25
|
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
|
|
Jul 25
|
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
|
Jun 24
|
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
|
|
Jun 21
|
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 20
|
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
Jun 20
|
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 17
|
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
|
|
May 16
|
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
|
|
May 16
|
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
|
|
May 15
|
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
May 15
|
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
|
|
May 15
|
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 15
|
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
May 14
|
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
|
|
May 13
|
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
|
May 13
|
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 10
|
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
|
|
May 7
|
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
|